ASCRS

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Mittwoch, März 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

Surface Ophthalmics Announces New Leadership with Richard Lindstrom, MD, and Renewed Vision for Addressing Critical Unmet Needs of Dry Eye Syndrome Patients

Retrieved on: 
Mittwoch, März 13, 2024
Biotechnology, Pharmaceutical, Optical, Health, International Society, Partnership, DES, ASCRS, Patient, Ophthalmology, Surface, University, Dry, MD, Refraction, Cataract, Eye, Mycophenolic acid, Society, Dry eye syndrome, Lead, Pharmaceutical industry

Surface Ophthalmics , a pioneering biopharmaceutical company, dedicated to transforming the management and treatment of dry eye syndrome (DES), today announced the appointment of Richard Lindstrom, MD as Founder & Chairman.

Key Points: 
  • Surface Ophthalmics , a pioneering biopharmaceutical company, dedicated to transforming the management and treatment of dry eye syndrome (DES), today announced the appointment of Richard Lindstrom, MD as Founder & Chairman.
  • A highly acclaimed physician and surgeon in ophthalmology, Dr. Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants, P.A.
  • Dr. Lindstrom will lead in partnership with Surface’s distinguished Board of Directors including Adrienne Graves, Ph.D., (Lead Director); Perry J. Sternberg, Shelley Thunen, and J. Andy Corley.
  • Dr. Richard Lindstrom is founder and attending surgeon emeritus at Minnesota Eye Consultants P.A., a provider of eye care services, since 1989.

US Eye Chief Medical Officer Dr. Kerry Solomon Honored with AECOS Award

Retrieved on: 
Dienstag, März 12, 2024
General Health, Surgery, Other Health, Health, Optical, Retina, Congress, Education, Eye, Refractive surgery, Physician, ASCRS, Patient, Research, Cataract, Surgeon, Society, Southeastern United States, Eye surgery, Multimedia, FDA, Ophthalmology, Medical device

View the full release here: https://www.businesswire.com/news/home/20240312937973/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240312937973/en/
    Kerry Solomon, M.D., US Eye Chief Medical Officer (Photo: Business Wire)
    Speaking of the Dulaney Award, Dr. Solomon comments, “I am incredibly proud to be the recipient of this year’s Dulaney Award.
  • Dr. Solomon currently serves as the Chief Medical Officer at US Eye, a physician-led network of eye care practices across the Southeastern United States and is a LASIK and Laser Cataract Surgeon at Carolina Eyecare Physicians in Mount Pleasant, South Carolina.
  • To that end, Dr. Solomon truly embodies the purpose of the AECOS Dulaney Award.
  • We are proud to work beside him and experience his impactful contributions firsthand,” said Brad Logan, CEO of US Eye.

ViaLase to Present Clinical Data at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Retrieved on: 
Dienstag, April 2, 2024
Laser, Glaucoma, Flight, Refractive surgery, ASCRS, BCEC, Patient, Doctor of Philosophy, Cataract, Society, Safety, Physician, Annual general meeting, Medical imaging

ALISA VIEJO, Calif., April 2, 2024 /PRNewswire/ -- ViaLase, Inc ., a clinical stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced that it will present clinical data as well as provide a business and technology overview during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held April 5-8, 2024 in Boston, Massachusetts.

Key Points: 
  • ALISA VIEJO, Calif., April 2, 2024 /PRNewswire/ -- ViaLase, Inc ., a clinical stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, today announced that it will present clinical data as well as provide a business and technology overview during the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held April 5-8, 2024 in Boston, Massachusetts.
  • We are excited to share the latest clinical data demonstrating the safety and efficacy of the ViaLase Laser at ASCRS.
  • ViaLase recently announced that it had completed a Series C round of financing, which will fund continued advancement of clinical, regulatory, and commercial milestones for the ViaLase® Laser.
  • The corporate and clinical presentations are scheduled as follows:
    Location: BCEC - Meeting Level 2, Room 259A
    *The ViaLase Laser is not approved for use in the United States.

ZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024

Retrieved on: 
Donnerstag, März 28, 2024
Glaucoma, Nomogram, ASCRS, Patient, Eye, SCI, Astigmatism, Surgeon, Workflow, 3D, Cataract, HDR, LVC, Biostatistics, Health, Food, 2D, Bed, Digital, Near-sightedness, Sharp HealthCare, FDA, Movement, LASIK, Temperature, SMILE, Refractive surgery, RGB, News, Silicon, Workplace, Society, Retina, Human, Telescopic sight

Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.

Key Points: 
  • Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.
  • Spatial Computing Innovation: ZEISS will demonstrate a digital application for experiencing 3D videos and more on the Apple Vision Pro.
  • ZEISS is extending its workflow offerings with new surgical and visualization technologies at ASCRS.
  • At ASCRS, surgeons are invited to join the ZEISS SMILE Speed Competition in lenticule extraction with the new ZEISS VISUMAX 800.

ZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024

Retrieved on: 
Donnerstag, März 28, 2024
Glaucoma, Nomogram, ASCRS, Patient, Eye, SCI, Astigmatism, Surgeon, Workflow, 3D, Cataract, HDR, LVC, Biostatistics, Health, Food, 2D, Bed, Digital, Near-sightedness, Sharp HealthCare, FDA, Movement, LASIK, Temperature, SMILE, Refractive surgery, RGB, News, Silicon, Workplace, Society, Retina, Human, Telescopic sight

Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.

Key Points: 
  • Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.
  • Spatial Computing Innovation: ZEISS will demonstrate a digital application for experiencing 3D videos and more on the Apple Vision Pro.
  • ZEISS is extending its workflow offerings with new surgical and visualization technologies at ASCRS.
  • At ASCRS, surgeons are invited to join the ZEISS SMILE Speed Competition in lenticule extraction with the new ZEISS VISUMAX 800.

Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments

Retrieved on: 
Mittwoch, Februar 28, 2024
ASRS, Senior, Paris Diderot University, SAB, Reno 1868 FC, Growth, Visual acuity, University, DED, Telecanthus, Organization, Principal, Teaching hospital, Retina, Anthropology, Diabetic retinopathy, Therapy, OCS, Inflammation, CSO, DME, American Academy, Simmons University, M.A, Clinical research, ASCRS, Society, Cerebral edema, Eastern Virginia Medical School, Patient, Partner (business rank), Medicine, Pharmaceutical industry

In-person and virtual R&D Day today from 9:00 AM to 11:00 AM EST at the InterContinental New York Barclay.

Key Points: 
  • In-person and virtual R&D Day today from 9:00 AM to 11:00 AM EST at the InterContinental New York Barclay.
  • “2024 promises to be another exciting year for Oculis as we advance our late-stage clinical development programs.
  • I am certain that the extensive experience each of them brings will be invaluable to Oculis,” said Riad Sherif, M.D., Chief Executive Officer of Oculis.
  • Oculis also announced today key executive appointments to bolster its leadership and scientific advisory teams.

STAAR Surgical Reports Fourth Quarter and Fiscal Year 2023 Results

Retrieved on: 
Montag, Februar 26, 2024
Optical, Health, Surgery, Medical Devices, Y/Y, Astigmatism, EVO, ICL, Research, Investment, Patient satisfaction, Marketing, Presbyopia, Growth, Table, Sale, Access, STAAR, ASCRS, Adjustment, Earnings, Advertising, GAAP, Near-sightedness, Depreciation, Pharmaceutical industry

Gross profit margin for the fourth quarter of 2023 was 79.6% of total net sales compared to the prior year quarter of 77.7% of total net sales.

Key Points: 
  • Gross profit margin for the fourth quarter of 2023 was 79.6% of total net sales compared to the prior year quarter of 77.7% of total net sales.
  • Product mix favorably impacted gross margin in the fourth quarter of 2023 as compared to the prior year quarter.
  • Operating expenses for the fourth quarter of 2023 were $50.3 million compared to the prior year quarter of $48.8 million.
  • Operating income for the fourth quarter of 2023 was $10.4 million or 13.7% of net sales as compared to $1.0 million or 1.5% of net sales for the fourth quarter of 2022.

CorNeat EverPatch Hits the US Market: Farewell to Traditional Ocular Tissue Grafts

Retrieved on: 
Dienstag, Februar 27, 2024
Cataract, FDA, Surgeon, ASCRS, Entrepreneurship, Safety, Refractive surgery, Society, Sclera, AGS, American Glaucoma Society

RA'ANANA, Israel, Feb. 27, 2024 /PRNewswire/ -- CorNeat Vision, a leader in innovative medical device solutions, proudly introduces the CorNeat EverPatch, a pioneering synthetic tissue-integrating matrix designed to revolutionize ophthalmic surgeries. Endorsed by leading surgeons across the US, this FDA-cleared device represents a significant leap forward in addressing complications related to surgical interventions of the ocular surface.

Key Points: 
  • The CorNeat EverPatch is a synthetic tissue substitute for ocular surface surgeries, offering a unique combination of features that provide a significant advantage over existing tissue grafts, which degrade over time.
  • The CorNeat EverPatch is poised to provide an optimal solution for reinforcing tissue over glaucoma drainage devices, addressing complications such as tube exposure that often require reoperation.
  • Dr. Gilad Litvin, Co-Founder and Chief Medical Officer at CorNeat Vision, emphasizes the safety and efficacy of the CorNeat EverPatch, stating, "Our synthetic tissue substitute is tear-resistant, non-degradable, and completely bio-compatible, with no observed chronic inflammatory response that exists around tissue grafts.
  • We are confident that the CorNeat EverPatch will set a new standard of care in ocular surgeries necessitating scleral reinforcement."

Stuart Therapeutics Announces Chief Medical and Chief Financial Officer Appointments

Retrieved on: 
Donnerstag, Februar 1, 2024
Principal, Public key certificate, Cordis, MD, Society, FDA, Columbia University, International Society, Book, Family, American Academy, Cataract, Don, Lehigh University, Culture, University, Refraction, ASCRS, Refractive surgery, Growth, American College, Mount Sinai Medical Center, Publication, Wills Eye Hospital, CFO, Congress, Therapy, Eye surgery, MBA, Executive, Accounting

STUART, Fla., Feb. 1, 2024 /PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today announced that it has appointed Jodi Luchs, MD to the position of Chief Medical Officer, and Don Stires to the position of Chief Financial Officer.

Key Points: 
  • STUART, Fla., Feb. 1, 2024 /PRNewswire/ -- Stuart Therapeutics, Inc. ("Stuart"), a clinical-stage biopharmaceutical company with candidate therapeutics in various phases of clinical development, today announced that it has appointed Jodi Luchs, MD to the position of Chief Medical Officer, and Don Stires to the position of Chief Financial Officer.
  • With the appointment of Dr. Luchs, Robert Baratta, MD has stepped aside from his current role as Chief Medical Officer but will continue as Stuart's Executive Chairman of the Board.
  • "Stuart Therapeutics' growth, international operations and increase in pipeline opportunities require an expansion of our team and capabilities," said Eric Schlumpf, President and Chief Executive Officer of Stuart.
  • He completed an internship at the Mount Sinai Medical Center, and his Ophthalmology residency at Long Island Jewish Medical Center.